Vaxalto Biotherapeutics is a pre-clinical stage biotechnology company focused on developing and commercializing viral immunotherapies. Our proprietary, multimodal virus platform has been engineered to potently stimulate the immune system against cancer, providing uniquely safe and effective treatment. Scientific leadership consists of experts in virology, immunology, vaccines, and cancer biology from the Icahn School of Medicine at Mount Sinai in New York.